Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABCL AbCellera Biologics	$4.48 +14.9%	$3.03	$1.89 ▼ $4.70	$1.16B	0.62	3.62 million shs	11.57 million shs
ALT Altimmune	$4.08 +0.7%	$5.49	$2.90 ▼ $11.16	$328.48M	0.47	3.38 million shs	3.49 million shs
HROW Harrow	$35.89 -0.7%	$30.13	$20.85 ▼ $59.23	$1.33B	0.41	500,180 shs	482,017 shs
PAHC Phibro Animal Health	$29.41 -1.1%	$25.63	$16.16 ▼ $31.80	$1.21B	0.75	224,464 shs	353,025 shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABCL AbCellera Biologics	-3.94%	-8.24%	+25.00%	+61.16%	+15.73%
ALT Altimmune	-3.11%	-7.95%	-41.22%	-11.09%	-45.93%
HROW Harrow	+4.60%	+15.21%	+18.84%	+50.65%	+43.70%
PAHC Phibro Animal Health	-2.65%	-4.53%	+21.60%	+71.95%	+56.31%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABCL AbCellera Biologics	2.3336 of 5 stars	3.5	1.0	0.0	0.0	2.7	3.3	0.0
ALT Altimmune	2.2152 of 5 stars	3.4	1.0	0.0	0.0	3.1	1.7	0.6
HROW Harrow	2.3876 of 5 stars	3.5	1.0	0.0	0.0	2.4	2.5	0.6
PAHC Phibro Animal Health	4.0499 of 5 stars	0.9	4.0	2.5	1.1	3.3	3.3	2.5

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABCL AbCellera Biologics	3.00	Buy	$8.75	95.31% Upside
ALT Altimmune	2.75	Moderate Buy	$18.20	346.08% Upside
HROW Harrow	3.00	Buy	$63.83	77.86% Upside
PAHC Phibro Animal Health	1.83	Reduce	$24.40	-17.04% Downside

Current Analyst Ratings Breakdown

Latest ALT, HROW, PAHC, and ABCL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/14/2025	ABCL AbCellera Biologics	KeyCorp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$5.00 ➝ $10.00
7/11/2025	HROW Harrow	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$76.00
7/10/2025	ALT Altimmune	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong Sell
7/10/2025	ALT Altimmune	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Market Outperform ➝ Market Outperform	$25.00 ➝ $15.00
7/7/2025	ABCL AbCellera Biologics	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/7/2025	ABCL AbCellera Biologics	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$5.00
7/7/2025	PAHC Phibro Animal Health	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Overweight	$25.00 ➝ $35.00
6/27/2025	ALT Altimmune	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform ➝ Market Perform
6/27/2025	ALT Altimmune	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$12.00
6/25/2025	PAHC Phibro Animal Health	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Equal Weight ➝ Equal Weight	$21.00 ➝ $26.00
6/16/2025	PAHC Phibro Animal Health	BNP Paribas Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold

(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABCL AbCellera Biologics	$28.83M	46.37	N/A	N/A	$3.58 per share	1.25
ALT Altimmune	$20K	16,546.44	N/A	N/A	$1.74 per share	2.34
HROW Harrow	$199.61M	6.60	$0.14 per share	264.30	$1.95 per share	18.41
PAHC Phibro Animal Health	$1.19B	1.00	$2.09 per share	14.06	$6.34 per share	4.64

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABCL AbCellera Biologics	-$162.86M	-$0.56	N/A	N/A	N/A	-737.56%	-15.98%	-12.38%	8/7/2025 (Estimated)
ALT Altimmune	-$95.06M	-$1.26	N/A	N/A	N/A	-451,200.00%	-65.44%	-58.43%	8/6/2025 (Estimated)
HROW Harrow	-$17.48M	-$0.56	N/A	89.73	N/A	-10.19%	-25.01%	-4.27%	8/6/2025 (Estimated)
PAHC Phibro Animal Health	$2.42M	$0.78	37.71	14.00	0.50	2.68%	30.51%	6.89%	8/27/2025 (Estimated)

Latest ALT, HROW, PAHC, and ABCL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	ALT Altimmune	-$0.3006	N/A	N/A	N/A	$0.00 million	N/A
8/7/2025	Q2 2025	ABCL AbCellera Biologics	-$0.17	N/A	N/A	N/A	$7.55 million	N/A
8/6/2025	Q2 2025	HROW Harrow	$0.01	N/A	N/A	N/A	$64.23 million	N/A
5/13/2025	Q1 2025	ALT Altimmune	-$0.35	-$0.26	+$0.09	-$0.26	$0.00 million	$0.01 million
5/8/2025	Q1 2025	ABCL AbCellera Biologics	-$0.17	-$0.15	+$0.02	-$0.15	$7.12 million	$4.24 million
5/8/2025	Q1 2025	HROW Harrow	$0.02	-$0.38	-$0.40	-$0.50	$57.00 million	$47.83 million
5/7/2025	Q3 2025	PAHC Phibro Animal Health	$0.52	$0.63	+$0.11	$0.51	$352.41 million	$347.80 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABCL AbCellera Biologics	N/A	N/A	N/A	N/A	N/A
ALT Altimmune	N/A	N/A	N/A	N/A	N/A
HROW Harrow	N/A	N/A	N/A	N/A	N/A
PAHC Phibro Animal Health	$0.48	1.63%	N/A	61.54%	N/A

Latest ALT, HROW, PAHC, and ABCL Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
5/6/2025	PAHC Phibro Animal Health	quarterly	$0.12	2.52%	6/4/2025	6/4/2025	6/25/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABCL AbCellera Biologics	N/A	10.15	10.15
ALT Altimmune	N/A	15.85	15.85
HROW Harrow	2.01	0.91	0.85
PAHC Phibro Animal Health	2.67	2.91	1.23

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABCL AbCellera Biologics	61.42%
ALT Altimmune	78.05%
HROW Harrow	72.76%
PAHC Phibro Animal Health	99.34%

Insider Ownership

Company	Insider Ownership
ABCL AbCellera Biologics	28.90%
ALT Altimmune	4.10%
HROW Harrow	15.16%
PAHC Phibro Animal Health	50.07%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABCL AbCellera Biologics	500	298.42 million	212.18 million	Optionable
ALT Altimmune	50	81.11 million	77.78 million	Optionable
HROW Harrow	180	36.69 million	31.12 million	Optionable
PAHC Phibro Animal Health	1,940	40.53 million	20.24 million	Optionable

ALT, HROW, PAHC, and ABCL Headlines

Recent News About These Companies

Hussman Strategic Advisors Inc. Grows Stock Holdings in Phibro Animal Health Corporation (NASDAQ:PAHC)

July 18 at 10:38 AM | marketbeat.com

Jackson Creek Investment Advisors LLC Makes New Investment in Phibro Animal Health Corporation (NASDAQ:PAHC)

July 18 at 10:08 AM | marketbeat.com

Pzena Investment Management LLC Has $15.46 Million Position in Phibro Animal Health Corporation (NASDAQ:PAHC)

July 18 at 9:00 AM | marketbeat.com

Phibro Animal Health Corporation (NASDAQ:PAHC) Stock Holdings Trimmed by Teacher Retirement System of Texas

July 18 at 3:13 AM | marketbeat.com

Should Value Investors Buy Phibro Animal Health (PAHC) Stock?

July 17 at 10:41 AM | zacks.com

Best Growth Stocks to Buy for July 17th

July 17 at 6:06 AM | zacks.com

3 Reasons Why Growth Investors Shouldn't Overlook Phibro (PAHC)

July 16 at 1:46 PM | zacks.com

PAHC or BSX: Which Is the Better Value Stock Right Now?

July 16 at 12:41 PM | zacks.com

Best Growth Stocks to Buy for July 15th

July 15 at 6:20 AM | zacks.com

4 Stocks Trading Near 52-Week High With More Upside Potential

July 14, 2025 | zacks.com

PAHC Phibro Animal Health Corporation - Seeking Alpha

July 12, 2025 | seekingalpha.com

Phibro Animal Health (PAHC) is a Great Momentum Stock: Should ... - Nasdaq

July 12, 2025 | nasdaq.com

Phibro Animal Health (PAHC) is a Great Momentum Stock: Should You Buy?

July 11, 2025 | msn.com

Here's Why Phibro Animal Health (PAHC) is a Strong Momentum Stock

July 11, 2025 | zacks.com

Phibro Animal Health Corporation (NASDAQ:PAHC) Given Consensus Rating of "Reduce" by Analysts

July 11, 2025 | marketbeat.com

Phibro Animal Health (PAHC) is a Great Momentum Stock: Should You Buy?

July 10, 2025 | zacks.com

Best Growth Stocks to Buy for July 10th

July 10, 2025 | zacks.com

Invest in 4 Winning Stocks With Proven Relative Price Power

July 9, 2025 | zacks.com

Phibro Animal Health (NASDAQ:PAHC) Upgraded by JPMorgan Chase & Co. to "Overweight" Rating

July 9, 2025 | americanbankingnews.com

JP Morgan Upgrades Phibro Animal Health (PAHC)

July 8, 2025 | msn.com

Phibro (PAHC) Soars 6.8%: Is Further Upside Left in the Stock?

July 8, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

3 AI Infrastructure Stocks With Strong Growth, Not Hype
By Chris Markoch | June 26, 2025
View 3 AI Infrastructure Stocks With Strong Growth, Not Hype
Do They Know Something? Insiders & Congress Buy UnitedHealth
By Brian O'Connell | July 9, 2025
View Do They Know Something? Insiders & Congress Buy UnitedHealth
Forget the Weak Dollar—These 3 Travel Stocks Are Still Taking Off
By Chris Markoch | July 6, 2025
View Forget the Weak Dollar—These 3 Travel Stocks Are Still Taking Off
Insiders Spent Millions on These 3 Stocks Over the Past 2 Months
By Leo Miller | July 17, 2025
View Insiders Spent Millions on These 3 Stocks Over the Past 2 Months
Why Realty Income’s 5.59% Yield Makes It a Must-Buy REIT
By Jeffrey Neal Johnson | July 2, 2025
View Why Realty Income’s 5.59% Yield Makes It a Must-Buy REIT

ALT, HROW, PAHC, and ABCL Company Descriptions

AbCellera Biologics NASDAQ:ABCL

$4.48 +0.58 (+14.87%)

Closing price 04:00 PM Eastern

Extended Trading

$4.50 +0.02 (+0.47%)

As of 08:00 PM Eastern

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.

Altimmune NASDAQ:ALT

$4.08 +0.03 (+0.74%)

Closing price 04:00 PM Eastern

Extended Trading

$4.10 +0.02 (+0.49%)

As of 07:59 PM Eastern

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.

Harrow NASDAQ:HROW

$35.89 -0.25 (-0.69%)

Closing price 04:00 PM Eastern

Extended Trading

$36.60 +0.70 (+1.96%)

As of 06:34 PM Eastern

Harrow, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in Nashville, Tennessee.

Phibro Animal Health NASDAQ:PAHC

$29.41 -0.32 (-1.08%)

Closing price 04:00 PM Eastern

Extended Trading

$29.44 +0.03 (+0.10%)

As of 07:04 PM Eastern

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. It also offers animal health products, such as antibacterials, anticoccidials, nutritional specialty, and vaccines and vaccine adjuvants for animal's health and performance, food safety, and animal welfare; and engages in development, manufacturing, and marketing of microbial and bioproducts for various applications serving animal health and nutrition, environmental, industrial, and agricultural customers. In addition, the company develops, manufactures, and markets conventionally licensed and autogenous vaccine products, as well as adjuvants for animal vaccine manufacturers. Further, it provides formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds to fortify the daily feed requirements of their livestock's diets and maintain optimal balance of trace elements in animals. Additionally, the company offers specialty ingredients for personal care, industrial chemical, and chemical catalyst industries. It sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle producers, as well as through commercial animal feed manufacturers, wholesalers, and distributors. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was founded in 1946 and is headquartered in Teaneck, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time